Biomark X Dotaz Zobrazit nápovědu
Mikrofluidika je inovativní obor, který se zabývá zpracováním malého množství kapaliny v mikrokanálech. V kombinaci s pokročilými analytickými technikami, jako je např. mikrofluidní PCR, nabízí významné výhody nejen pro analýzu genové exprese. Tato metoda využívá mikrokanály a mikroventily k přesnému dávkování a míchání činidel, čímž se minimalizuje spotřeba vzorku a činidla a také čas stráve‐ ný pipetováním. Tyto vlastnosti činí mikrofluidní PCR ideální pro analýzu genové exprese, kde je vyžadováno podrobné monitorování a kvantifikace mRNA. Jedním z přístrojů umožňujícím mikrofluidní PCR je Biomark X. Díky své schopnosti multiplexování a také díky své‐ mu mikrofluidnímu designu umožňuje analýzu mnoha vzorků současně. Tato pokročilá technologie má široké uplatnění v biologickém výzkumu, diagnostice a personalizované medicíně a nabízí nové příležitosti k objevování a pochopení genetických procesů.
Microfluidics is an innovative science that deals with the manipulation of small volumes of fluid in microchannels. In combination with advanced analytical techniques such as microfluidic PCR, it offers significant advantages not only for gene expression analysis. Microflui‐ dic PCR enables PCR reactions to be performed using very small sample volumes, as it utilizes microchannels and microvalves for precise reagent dispensing and mixing. This fact increases both sensitivity and accuracy of the analysis. The Biomark X instrument utilizes micro‐ fluidic PCR for gene expression analysis, as it is ideal for mRNA quantification. With its multiplexing capability and microfluidic design, it enables the analysis of multiple samples simultaneously. This advanced technology finds broad applications in biological research, diagnostics, and provides new opportunities for the discovery and understanding of genetic processes.
X-linked Adrenoleukodystrophy (X-ALD) is caused by mutations in the ABCD1 gene resulting in the accumulation of very long chain fatty acids (VLCFA). X-ALD is the most common peroxisomal disorder with adult patients (male and female) presenting with progressive spastic paraparesis with bladder disturbance, sensory ataxia with impaired vibration sense, and leg pain. 80% of male X-ALD patients have an adrenal failure, while adrenal dysfunction is rare in women with X-ALD. The objective of this study was to define optimal serum VLCFA cutoff values in patients with X-ALD-like phenotypes for the differentiation of genetically confirmed X-ALD and Non-X-ALD individuals. Three groups were included into this study: a) X-ALD cases with confirmed ABCD1 mutations (n = 34) and two Non-X-ALD cohorts: b) Patients with abnormal serum VCLFA levels despite negative testing for ABCD1 mutations (n = 15) resulting from a total of 1,953 VLCFA tests c) Phenotypically matching patients as Non-X-ALD controls (n = 104). Receiver operating curve analysis was used to optimize VLCFA cutoff values, which differentiate patients with genetically confirmed X-ALD and Non-X-ALD individuals. The serum concentration of C26:0 was superior to C24:0 for the detection of X-ALD. The best differentiation of Non-X-ALD and X-ALD individuals was obtained with a cutoff value of < 1.0 for the C24:0/C22:0 ratio resulting in a sensitivity of 97%, a specificity of 94.1% and a positive predictive value (PPV) of 83.8% for true X-ALD. Our findings further suggested a cutoff of < 0.02 for the ratio C26:0/C22:0 leading to a sensitivity of 90.9%, a specificity of 95.0%, and a PPV of 80.6%. Pearson correlation indicated a significant positive association between total blood cholesterol and VLCFA values. Usage of serum VLCFA are economical and established biomarkers suitable for the guidance of genetic testing matching the X-ALD phenotype. We suggest using our new optimized cutoff values, especially the two ratios (C24:0/C22:0 and C26:0/C22:0), in combination with standard lipid profiles.
- MeSH
- ABC transportéry genetika MeSH
- adrenoleukodystrofie krev diagnóza MeSH
- astrocyty patologie MeSH
- biologické markery krev MeSH
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- mastné kyseliny krev MeSH
- mutace genetika MeSH
- senioři MeSH
- senzitivita a specificita MeSH
- Check Tag
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
Objective: Photobiomodulation therapy (PBMT) applies therapeutic lasers or light-emitting diodes radiation to the surface of the body. From the medical point of view, PBMT systems have been employed for reducing pain, inflammation, and edema, promoting healing of wounds, deeper tissues and nerves, preventing tissue damage, etc. Background data: PBMT or biostimulation has a wide range of applications in maxillofacial surgery. It is known that the therapy effect using three-dimensional (3D) image was not really clear during the healing process. Materials and methods: The treatment group comprised 38 patients, 18 of them were treated with laser radiation (diode laser 808 nm) and 20 patients presented the control group. The surgery plan was monitored using cone beam computed tomography, in particular the number, shape, and size of mesiodens were registered. The effectivity of laser therapy was assessed based on immunological tests-secretory immunoglobulin A (sIgA) and lysozyme levels measured in nonstimulated saliva before and after treatment. Results: For sIgA (both in millimeters and milligrams per liter), the measurements displayed differences between pre- and postsurgery values, the postsurgery values being significantly lower than the presurgery values. In addition, interaction with the laser treatment plan was found, meaning that the laser treatment affected the sIgA levels. The decrease in sIgA levels in the control group was statistically significant. However, there was no significant change in sIgA levels in the laser group. The lysozyme trends appeared to be identical to the sIgA levels, that is, rising in the laser group and decreasing in the control group. The initial values for each group, however, go in the opposite direction. Conclusions: The study has shown that the 3D techniques and technologies in combination with therapeutic laser systems could support not only a treatment plan, but they also directly influence the process of healing and reduce inflammation. The study was carried out under clinical project No. 00064203 (FN MOTOL).
Circulating miRNAs have been proposed as the effective diagnostic biomarkers for muscular fibrosis-associated diseases. However, circulating biomarkers for early diagnosis of contracture muscles are limited in gluteal muscle contracture (GMC) patients. Here we sought to explore the abnormally expressed miRNAs in plasma and contraction bands of GMC patients. The results showed miR-29a-3p expression in plasma and contraction bands tissue was significantly reduced in GMC patients compared with normal control. Cell viability and levels of proliferation-associated protein cyclin D1 and cyclin-dependent-kinase 2 (CDK2) were powerfully inhibited by miR-29a mimics and enhanced by miR-29a inhibitor compared with negative control. Furthermore, miR-29a mimics effectively impeded, while miR-29a inhibitor enhanced the expression of collagen I and collagen III, followed by the secretion of transforming growth factor beta1 (TGF-beta1), TGF-beta3 and connective tissue growth factor (CTGF) in primary human contraction bands (CB) fibroblasts. The miR-29a-3p negatively regulated the expression of TGF-beta1 through binding to the 3´ UTR region of SERPINH1 (encoding heat shock protein HSP47), but had no effect on Smad2 activity. The miR-29a-3p was inversely correlated with HSP47 in contraction bands tissue from GMC patients. Collectively, miR-29a was notably depressed and regulated cell viability and fibrosis by directly targeting HSP47 in GMC, which suggest that circulating miR-29a might be a potential biomarker for early diagnosis and provides a novel therapeutic target for GMC.
- MeSH
- biologické markery metabolismus MeSH
- dospělí MeSH
- fibroblasty metabolismus patologie MeSH
- fibróza genetika patologie prevence a kontrola MeSH
- hýždě patologie MeSH
- kontraktura genetika patologie prevence a kontrola MeSH
- kultivované buňky MeSH
- lidé MeSH
- mikro RNA genetika MeSH
- proteiny tepelného šoku HSP47 genetika metabolismus MeSH
- studie případů a kontrol MeSH
- svaly metabolismus patologie MeSH
- transformující růstový faktor beta1 genetika metabolismus MeSH
- viabilita buněk fyziologie MeSH
- Check Tag
- dospělí MeSH
- lidé MeSH
- mužské pohlaví MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
To determine the effect of saturated hydrogen saline on lipopolysaccharide (LPS)-induced acute liver dysfunction, rats were divided into control, LPS, and LPS plus saturated hydrogen saline (LPS+H(2)) groups. Treatment with saturated hydrogen saline prolonged the median survival time and reduced liver dysfunction. Moreover, saturated hydrogen saline significantly reduced pathological alterations in liver tissues, the number of ballooned hepatocytes, serum tumor necrosis factor (TNF)-alpha and interleukin (IL)-6 levels, and myeloperoxidase (MPO) and malondialdehyde (MDA) levels in liver tissues (P<0.05). Cell apoptosis was detected in liver tissues after LPS treatment, and attenuated by saturated hydrogen saline treatment. Saturated hydrogen saline also decreased phosphorylated extracellular signal-regulated kinase (p-ERK), phosphorylated Jun kinase (p-JNK), nuclear factor-kappa B (NF-kappaB), and second mitochondria-derived activator of caspase (Smac) levels, and increased p38 activation (P<0.05). Thus, saturated hydrogen saline may attenuate LPS-induced acute liver dysfunction in rats, possibly by reducing inflammation and cell apoptosis. Mitogen-activated protein kinase (MAPK), NF-kappaB, and Smac may contribute to saturated hydrogen saline-mediated liver protection.
- MeSH
- aktivace enzymů MeSH
- apoptóza účinky léků MeSH
- biologické markery krev MeSH
- chlorid sodný farmakologie MeSH
- extracelulárním signálem regulované MAP kinasy metabolismus MeSH
- fosforylace MeSH
- interleukin-6 krev MeSH
- játra účinky léků metabolismus patologie MeSH
- JNK mitogenem aktivované proteinkinasy metabolismus MeSH
- krysa rodu rattus MeSH
- lipopolysacharidy * MeSH
- malondialdehyd metabolismus MeSH
- mitochondriální proteiny metabolismus MeSH
- mitogenem aktivované proteinkinasy p38 metabolismus MeSH
- modely nemocí na zvířatech MeSH
- nemoci jater etiologie metabolismus patologie prevence a kontrola MeSH
- NF-kappa B metabolismus MeSH
- peroxidasa metabolismus MeSH
- potkani Sprague-Dawley MeSH
- TNF-alfa krev MeSH
- transportní proteiny metabolismus MeSH
- vodík farmakologie MeSH
- zvířata MeSH
- Check Tag
- krysa rodu rattus MeSH
- mužské pohlaví MeSH
- zvířata MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
Galectin-4 is thought to play a role in the process of tumour conversion of cells of the alimentary tract and the breast tissue; however, its exact function remains unknown. With the aim of elucidating the structural basis of mouse galectin-4 (mGal-4) binding specificity, we have undertaken X-ray analysis of the N-terminal domain, CRD1, of mGal-4 in complex with lactose (the basic building block of known galectin-4 carbohydrate ligands). Crystals of CRD1 in complex with lactose were obtained using vapour-diffusion techniques. The crystals belong to tetragonal space group P42(1)2 with unit-cell parameters a = 91.1, b = 91.16, c = 57.10 A and preliminary X-ray diffraction data were collected to 3.2 A resolution. An optimized crystallization procedure and cryocooling protocol allowed us to extend resolution to 2.1 A. Structure refinement is currently under way; the initial electron-density maps clearly show non-protein electron density in the vicinity of the carbohydrate binding site, indicating the presence of one lactose molecule. The structure will help to improve understanding of the binding specificity and function of the potential colon cancer marker galectin-4.
- MeSH
- aminokyselinové motivy MeSH
- difrakce rentgenového záření MeSH
- financování organizované MeSH
- galektin 4 chemie metabolismus MeSH
- krystalizace MeSH
- laktosa chemie metabolismus MeSH
- ligandy MeSH
- myši MeSH
- nádorové biomarkery chemie metabolismus MeSH
- nádory tračníku chemie metabolismus MeSH
- peptidové fragmenty chemie metabolismus MeSH
- terciární struktura proteinů MeSH
- vazebná místa MeSH
- zvířata MeSH
- Check Tag
- myši MeSH
- zvířata MeSH
- MeSH
- finanční podpora výzkumu jako téma MeSH
- hodnocení rizik MeSH
- klinické zkoušky jako téma ekonomika metody MeSH
- konsensus MeSH
- kontrolní seznam MeSH
- lidé MeSH
- nádorové biomarkery metabolismus MeSH
- nádory metabolismus terapie MeSH
- National Cancer Institute (U.S.) ekonomika MeSH
- řízení rizik MeSH
- rizikové faktory MeSH
- výběr pacientů MeSH
- výsledek terapie MeSH
- výzkumný projekt MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- práce podpořená grantem MeSH
- Geografické názvy
- Evropa MeSH
- Spojené státy americké MeSH
